Literature DB >> 18004405

Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues.

M Rao1.   

Abstract

Embryonic stem cells unlike most adult stem cell populations can replicate indefinitely while preserving genetic, epigenetic, mitochondrial and functional profiles. ESCs are therefore an excellent candidate cell type for providing a bank of cells for allogenic therapy and for introducing targeted genetic modifications for therapeutic intervention. This ability of prolonged self-renewal of stem cells and the unique advantages that this offers for gene therapy, discovery efforts, cell replacement, personalized medicine and other more direct applications requires the resolution of several important manufacturing, gene targeting and regulatory issues. In this review, we assess some of the advance made in developing scalable culture systems, improvement in vector design and gene insertion technology and the changing regulatory landscape.

Entities:  

Mesh:

Year:  2007        PMID: 18004405     DOI: 10.1038/sj.gt.3303061

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

Review 1.  Concise review: making and using clinically compliant pluripotent stem cell lines.

Authors:  Melissa K Carpenter; Mahendra S Rao
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

Review 2.  Alternative sources of pluripotent stem cells: ethical and scientific issues revisited.

Authors:  Maureen L Condic; Mahendra Rao
Journal:  Stem Cells Dev       Date:  2010-08       Impact factor: 3.272

3.  Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.

Authors:  Mehdi Dashtban; Krishna Morgan Panchalingam; Mehdi Shafa; Behnam Ahmadian Baghbaderani
Journal:  Methods Mol Biol       Date:  2021

4.  Non-muscle myosin II regulates survival threshold of pluripotent stem cells.

Authors:  Andrea Walker; Hua Su; Mary Anne Conti; Nicole Harb; Robert S Adelstein; Noboru Sato
Journal:  Nat Commun       Date:  2010-09-07       Impact factor: 14.919

5.  Regulatory issues for personalized pluripotent cells.

Authors:  Maureen L Condic; Mahendra Rao
Journal:  Stem Cells       Date:  2008-07-31       Impact factor: 6.277

6.  Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines.

Authors:  Lois A Annab; Carl D Bortner; Marie I Sifre; Jennifer M Collins; Ruchir R Shah; Darlene Dixon; H Karimi Kinyamu; Trevor K Archer
Journal:  Differentiation       Date:  2012-08-18       Impact factor: 3.880

7.  Derivation of Diverse Hormone-Releasing Pituitary Cells from Human Pluripotent Stem Cells.

Authors:  Bastian Zimmer; Jinghua Piao; Kiran Ramnarine; Mark J Tomishima; Viviane Tabar; Lorenz Studer
Journal:  Stem Cell Reports       Date:  2016-06-14       Impact factor: 7.765

8.  cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.

Authors:  Behnam Ahmadian Baghbaderani; Xinghui Tian; Boon Hwa Neo; Amy Burkall; Tracy Dimezzo; Guadalupe Sierra; Xianmin Zeng; Kim Warren; Don Paul Kovarcik; Thomas Fellner; Mahendra S Rao
Journal:  Stem Cell Reports       Date:  2015-09-24       Impact factor: 7.765

Review 9.  hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.

Authors:  Vikram Sabapathy; Sanjay Kumar
Journal:  J Cell Mol Med       Date:  2016-04-21       Impact factor: 5.310

10.  A Combination of Culture Conditions and Gene Expression Analysis Can Be Used to Investigate and Predict hES Cell Differentiation Potential towards Male Gonadal Cells.

Authors:  Kristín Rós Kjartansdóttir; Ahmed Reda; Sarita Panula; Kelly Day; Kjell Hultenby; Olle Söder; Outi Hovatta; Jan-Bernd Stukenborg
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.